Pyrukynd, which Agios sells for a rare type of anemia, missed one of its main objectives in a study seen as crucial for its ...

Agios reported mixed results from a Phase 3 study of its drug Pyrukynd in sickle cell, raising doubts about the drug's ...

Shares of Agios Pharmaceuticals, Inc. (AGIO) slumped 49% in the pre-market session on Wednesday after the company reported ...

Mitapivat met the hemoglobin endpoint but missed the endpoints for pain crises and fatigue, prompting concerns about the ...

Shares in Agios Pharma lost nearly half their value in pre-market trading today after it posted mixed clinical results from a ...

PRNewswire/ - Medunik USA, a specialty pharmaceutical company, and part of Duchesnay Pharmaceutical Group (DPG), is dedicated to providing patients with rare diseases access to orphan drugs. Medunik ...

The FDA will decide on a new sickle-cell drug, causing excitement and concern among physicians and patients. The time has come for the U.S. Food and Drug Administration (FDA) to decide on a new sickle ...

Shares of Agios Pharmaceuticals sank after the company said a phase three trial of its mitapivat drug to treat Sickle Cell Disease missed some of its endpoints. The stock fell 34% to $30 after closing ...

Agios Pharma reports mixed Phase 3 results for its sickle cell drug, mitapivat, highlighting the complex drug development and ...

This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. In the years since the approval of Imbruvica for ...

The NDDC launches a sickle cell awareness campaign in Delta, providing medical support, drugs, and education to patients and ...